4//SEC Filing
Kirk Christopher J. 4
Accession 0001209191-22-039526
CIK 0001645666other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 6:30 PM ET
Size
7.2 KB
Accession
0001209191-22-039526
Insider Transaction Report
Form 4
Kirk Christopher J.
DirectorCEO
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2022-06-23−33,060→ 123,361 totalExercise: $0.90Exp: 2025-09-09→ Common Stock (33,060 underlying) - Exercise/Conversion
Common Stock
2022-06-23$0.90/sh+33,060$29,754→ 381,484 total
Footnotes (2)
- [F1]Total reflects 1,953, 981, 986, 951 and 944 shares of common stock acquired on May 15, 2020, November 15, 2020, May 15, 2021, November 15, 2021 and May 15, 2022, respectively, through the Company's 2018 Employee Stock Purchase Plan.
- [F2]Fully vested and exercisable.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
Related Parties
1- filerCIK 0001744253
Filing Metadata
- Form type
- 4
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 6:30 PM ET
- Size
- 7.2 KB